MétaCan
Menu
Back to cohort
Record W4407387203 · doi:10.1093/ijnp/pyae059.640

THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ICLEPERTIN (BI 425809), A GLYCINE TRANSPORTER 1 INHIBITOR, IN HEALTHY VOLUNTEERS: A PHASE I OPEN-LABEL, RANDOMIZED, CROSSOVER TRIAL

2025· article· en· W4407387203 on OpenAlexaff
Akiko Harada, Shilpa Madari, Arvid Jungnik, Kerstin Breithaupt-Groegler, Kathrin Hohl

Bibliographic record

VenueThe International Journal of Neuropsychopharmacology · 2025
Typearticle
Languageen
FieldMedicine
TopicPharmaceutical studies and practices
Canadian institutionsBoehringer Ingelheim (Canada)
Fundersnot available
KeywordsOpen labelPharmacokineticsCrossover studyPharmacologyTransporterRandomized controlled trialMedicineGlycineBioequivalenceChemistryInternal medicineBiochemistryPlaceboAmino acid

Abstract

fetched live from OpenAlex

Abstract Background Iclepertin (BI 425809) is a glycine transporter 1 inhibitor being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS). Aims and Objectives To investigate the effect of food on the pharmacokinetics (PK) of iclepertin in healthy volunteers (HV). Methods This Phase I, open-label, two-period, two-sequence crossover trial included Caucasian HV (18–55 years of age). HV were randomized (1:1) to a single oral dose of iclepertin 10 mg (film-coated tablet) when fasted (reference, R) and following a standard high-fat, high-calorie meal (test, T), or received T then R. Iclepertin administrations were separated by a wash-out period of at least 14 days. The primary endpoints were area under the concentration– time curve over the time interval from 0 to the last quantifiable data point (AUC0-tz) and maximum measured concentration (Cmax) of iclepertin in plasma. The secondary endpoint was area under the concentration– time curve over the time interval from 0 extrapolated to infinity (AUC0-∞) of iclepertin in plasma. Relative bioavailability was estimated by calculating a geometric mean (gMean) T/R ratio using an analysis of variance. Safety and tolerability assessments included adverse event (AE) reporting; HVs with AEs were analysed descriptively. Results The 16 enrolled HV (9 women, 7 men) had a mean (standard deviation) age of 37.1 (10.1) years. The treatment adjusted gMean AUC0-tz, Cmax and AUC0-∞ and the adjusted gMean T/R ratios for the PK endpoints were higher following iclepertin 10 mg administration in the fed versus the fasted state (Table). Overall, 8/16 HV (50.0%) reported at least 1 AE; 6/16 HV (37.5%) reported drug-related AEs (fasted: 4/16 HV [25%]; fed: 3/15 HV [20.0%]) and headache was reported most frequently. Discussion and Conclusion Although the exposure (AUC0-tz, Cmax and AUC0-∞) and relative bioavailability of a single oral dose of iclepertin 10 mg was higher in the fed versus the fasted state, increases were deemed minor and not clinically meaningful. Further, iclepertin was generally well tolerated by Caucasian HV participating in this trial and no new safety signals were identified. These findings may be relevant to the Asian population (Rosenbrock et al., 2023). Funding Boehringer Ingelheim (1346-0053; NCT05347004). References Rosenbrock, H., Desch, M. and Wunderlich, G. (2023). Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci, 273(7), pp.1557–1566.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.069
GPT teacher head0.446
Teacher spread0.377 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueThe International Journal of NeuropsychopharmacologySame topicPharmaceutical studies and practicesFrench-language works237,207